Skip to main content

Third Rock Ventures — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

50
Companies
$6.1B
Total invested
$136.5M
Avg. check
20
Industries
Biotechnology 22Therapeutics 11Health Care 11Medical 10Genetics 6Life Science 6+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 50
Red Arrow Therapeutics
September 2024

Red Arrow Therapeutics is a biotech firm that provides systemic cytokine delivery, targeted intratumoral activation, and biological potency.

Alternative Medicine · Minato$55.0M Series A
Abata Therapeutics
August 2024

Abata Therapeutics develops regulatory T cell (Treg) therapies for treating autoimmune diseases including progressive multiple sclerosis.

Biotechnology · CambridgeCorporate Round
Septerna
July 2023

Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.

Biotechnology · San Francisco$150.0M Series B
Rhythm Pharmaceuticals
July 2025

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics

Biotechnology · Boston$175.0M Post-IPO Equity
Marea Therapeutics
June 2024

Marea is a biotechnology company that develops therapies and medications for the treatment of cardioendocrine illness patients.

Biotechnology · San Francisco$190.0M Series B
Allena Pharmaceuticals
May 2022

Allena Pharmaceuticals develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.

Biotechnology · Newton$2.8M Post-IPO Equity
Editas Medicine
May 2026

Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.

Biotechnology · Cambridge$125.0M Post-IPO Equity
Relay Therapeutics
May 2026

Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.

Biotechnology · Cambridge$275.0M Post-IPO Equity
MOMA Therapeutics
May 2022

MOMA Therapeutics operates as a biotechnology company.

Biotechnology · Cambridge$150.0M Series B
Merida Biosciences
April 2025

Merida Biosciences is a biotech company focused on developing precision treatments, particularly for autoimmune diseases.

Biotechnology · Cambridge$121.0M Series A
Revolution Medicines
April 2026

Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.

Health Care · Redwood City$1.5B Post-IPO Equity
Celsius Therapeutics
March 2022

Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.

Biotechnology · Cambridge$83.0M Series B
Casma Therapeutics
March 2026

Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.

Biotechnology · Cambridge$7.6M Grant
Genetix Biotherapeutics Inc.
February 2025

Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.

Biotechnology · SomervillePrivate Equity
ARTBIO
July 2025

ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.

Biotechnology · Cambridge$132.0M Series B
Corvia Medical
June 2025

Corvia Medical develops transcatheter device designed to reduce the symptoms or slow the progression of heart failure.

Biopharma · Andover$55.0M Venture - Series Unknown
Trace Neuroscience
November 2024

Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients.

Biotechnology · South San Francisco$101.0M Series A
Asher Bio
April 2024

Asher Bio is a biotechnology company that specializes in the fields of therapeutics builds better immunotherapy for cancer.

Biotechnology · San Francisco$55.0M Series C
Synnovation Therapeutics
December 2023

Synnovation Therapeutics is a precision oncology company that develops therapeutics that aims to help people with cancer.

Biotechnology · Wilmington$102.0M Series A
Voyager Therapeutics
January 2024

Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.

Biotechnology · Cambridge$100.0M Post-IPO Equity
Pliant Therapeutics
January 2023

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Biotechnology · South San Francisco$287.5M Post-IPO Equity
Ambys Medicines
December 2021

Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.

Biotechnology · South San Francisco$47.0M Series A
Global Blood Therapeutics
December 2021

GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.

Biotechnology · South San Francisco$300.0M Post-IPO Debt
Azalea Therapeutics
November 2025

Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.

Biotechnology · Berkeley$65.0M Series A

Where Third Rock Ventures invests

Biotechnology22
Therapeutics11
Health Care11
Medical10
Genetics6
Life Science6

About Third Rock Ventures's portfolio

How many companies has Third Rock Ventures invested in?

Third Rock Ventures has invested in 50 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Third Rock Ventures invest in?

Third Rock Ventures's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Genetics. The firm invests across 20 different industry categories.

What is Third Rock Ventures's largest investment?

Among tracked funding rounds, Revolution Medicines received $1.5B in a Post-IPO Equity round. Third Rock Ventures's total known invested capital is $6.1B.

What is the average investment size for Third Rock Ventures?

Third Rock Ventures's average investment size is $136.5M across its portfolio of 50 companies.

What are Third Rock Ventures's most recent investments?

Recent Third Rock Ventures portfolio additions include Red Arrow Therapeutics, Abata Therapeutics, Septerna, Rhythm Pharmaceuticals, Marea Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 50 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →